Scholarlink

Purpose <p>Periodontitis is a chronic inflammatory disease which can ultimately lead to tooth loss. This research aimed to develop a thermosensitive in-situ gel (ISG) for the localized administration and study the effect of varying concentrations (Conc.) of levofloxacin (Lvx) within periodontal pockets.</p> Methods <p>25 mixtures of different concentrations of poloxamer (Polx) 407 (16%-20%) and Polx188 (1%-4%) were formulated; four were selected: P2 (Polx 407 17%), P14 (Polx 407 19% and Polx 188 3%), P19 (Polx 407 19% and Polx188 2%), and P22 (Polx 407 17% and Polx188 1%). Mucoadhesive polymers were added to the chosen four formulations (Methyl Cellulose (MC) 0.25%-1%, Hydroxypropyl methylcellulose (HPMC) 0.1%-0.3%, Gellan gum (GG) 0.2%-0.6%, Chitosan (Chts) 0.5%-1.5%, Carbopol (Car) 0.05%-0.15%), resulted in 60 combinations. After assessing factors such as viscosity and gelation, three formulations were chosen: A7 (Polx407 17% GG 0.2%), A10 (Polx407 17% Chts 0.5%), and A19 (Polx407 17% Polx188 1% HPMC 0.1%) for further investigations. the antibacterial effects of various Conc. of Lvx (0.5%-5%) on these formulations, specifically incorporating them into the A10 (Polx407 17% Chts 0.5%) formulation.</p> Results <p>All tested concentrations of levofloxacin exhibited impressive inhibition zones ranging from 31 to 45 mm in comparison to positive control (14-15mm). 0.5% and 1% Conc. of Lvx where chosen, which were then incorporated, resulting in six formulations for evaluation Lvx, resulting in six final formulations. These were evaluated for drug release, antibacterial activity, and stability.</p> Conclusions <p>Formulations F1 and F2 exhibited sustained Lvx release and demonstrated significant efficacy against bacteria. In conclusion, F1 and F2 promise to develop a prolonged-release ISG for delivering Lvx in treating periodontitis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preparation and In-Vitro Evaluation of Thermosensitive In-Situ Gel with Different Concentrations of Levofloxacin for Periodontal Applications

  • 期刊论文

  • 发表日期：

    2025年6月6日

查看全文
  • Abdulla Riyadh Al-Dabbagh,
  • Mohanad A. Alfahad

摘要

Purpose

Periodontitis is a chronic inflammatory disease which can ultimately lead to tooth loss. This research aimed to develop a thermosensitive in-situ gel (ISG) for the localized administration and study the effect of varying concentrations (Conc.) of levofloxacin (Lvx) within periodontal pockets.

Methods

25 mixtures of different concentrations of poloxamer (Polx) 407 (16%-20%) and Polx188 (1%-4%) were formulated; four were selected: P2 (Polx 407 17%), P14 (Polx 407 19% and Polx 188 3%), P19 (Polx 407 19% and Polx188 2%), and P22 (Polx 407 17% and Polx188 1%). Mucoadhesive polymers were added to the chosen four formulations (Methyl Cellulose (MC) 0.25%-1%, Hydroxypropyl methylcellulose (HPMC) 0.1%-0.3%, Gellan gum (GG) 0.2%-0.6%, Chitosan (Chts) 0.5%-1.5%, Carbopol (Car) 0.05%-0.15%), resulted in 60 combinations. After assessing factors such as viscosity and gelation, three formulations were chosen: A7 (Polx407 17% GG 0.2%), A10 (Polx407 17% Chts 0.5%), and A19 (Polx407 17% Polx188 1% HPMC 0.1%) for further investigations. the antibacterial effects of various Conc. of Lvx (0.5%-5%) on these formulations, specifically incorporating them into the A10 (Polx407 17% Chts 0.5%) formulation.

Results

All tested concentrations of levofloxacin exhibited impressive inhibition zones ranging from 31 to 45 mm in comparison to positive control (14-15mm). 0.5% and 1% Conc. of Lvx where chosen, which were then incorporated, resulting in six formulations for evaluation Lvx, resulting in six final formulations. These were evaluated for drug release, antibacterial activity, and stability.

Conclusions

Formulations F1 and F2 exhibited sustained Lvx release and demonstrated significant efficacy against bacteria. In conclusion, F1 and F2 promise to develop a prolonged-release ISG for delivering Lvx in treating periodontitis.